Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints

Dow Jones

2025/01/02

By Denny Jacob

Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement.

Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60.

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale.

"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing," said Chief Executive Henry Gosebruch.

Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 02, 2025 07:17 ET (12:17 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2500940041"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500940041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500940041?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500940041","market":"other","top_or_hot":-1,"title":"Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n</p>\n<p>\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n</p>\n<p>\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n</p>\n<p>\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 07:17 ET (12:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-02 20:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n</p>\n<p>\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n</p>\n<p>\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n</p>\n<p>\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 07:17 ET (12:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2500940041","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500940041","pubTimestamp":1735820220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement.Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60.The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale.\"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch.Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","BK4139":"生物科技","NMRA":"Neumora Therapeutics, Inc."},"translate_title":"Neumora Therapeutics抑郁症治疗研究未达到主要和次要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NMRA":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. \n\n\n  Trading was halted at 6:55 a.m. ET ahead of the disclosure. The stock closed Tuesday at $10.60. \n\n\n  The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures depression at Week 6 or the key secondary endpoint of change from baseline in a separate scale. \n\n\n  \"The outcome of KOASTAL-1 is not what we expected, but there are encouraging trends in the data that we are analyzing,\" said Chief Executive Henry Gosebruch. \n\n\n  Neumora said navacaprant was shown to be safe and generally well-tolerated with no serious adverse events reported. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 07:17 ET (12:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}